Veracyte, Inc.

238 articles with Veracyte, Inc.

• Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis

  6/26/2019

  Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC) available to physicians, providing them with expanded lung cancer risk information that can further guide next steps for patients with suspicious lung nodules, as compared to the original Percepta test

• Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment

  6/17/2019

  Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment

• Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

  6/10/2019

  Veracyte, Inc. (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer diagnosis, as compared to the original Afirma test

• Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis

  6/1/2019

  Veracyte, Inc. announced new data demonstrating the potential for its Afirma® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients with a rare but aggressive form of thyroid cancer concurrent with diagnosis by the company’s Afirma Genomic Sequencing Classifier (GSC).

• Veracyte Announces Participation in Two Upcoming Investor Conferences

  5/29/2019

  The William Blair 39th Annual Growth Stock Conference in Chicago on Wednesday, June 5, 2019, at 2:00 p.m. CDT.

• Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting

  5/23/2019

  American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago.

• Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis

  5/20/2019

  Researchers prospectively validated the Percepta GSC on 412 patients with lung nodules who had inconclusive results following bronchoscopy, a common nonsurgical procedure to diagnose lung cancer.

• 

  BioSpace Movers and Shakers, May 17

  5/17/2019

  Biopharma companies add new leaders to executive roles and boards of directors.

• Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology

  5/14/2019

  Dr. Bhorade will lead medical affairs for Veracyte’s pulmonology products

• Veracyte to Present at the UBS Global Healthcare Conference

  5/9/2019

  Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on Monday, May 20, 2019 at 9:30 a.m. EDT.

• Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  5/7/2019

  Veracyte, Inc. announced the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $23.25 per share.

• Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock - May 2, 2019

  5/3/2019

  Veracyte, Inc. announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.25 per share.

• Veracyte Announces Proposed Public Offering of Common Stock - May 1, 2019

  5/1/2019

  Veracyte, Inc. announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.

• Veracyte Announces First Quarter 2019 Financial Results

  4/30/2019

  Veracyte, Inc. announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.

• Veracyte Names Alfred Bowie, Jr., Ph.D. as Vice President, Corporate and Business Development

  4/22/2019

  Dr. Bowie will lead the company’s strategic planning process and be responsible for identifying, evaluating and executing technology and business partnerships, licensing and acquisitions as well as managing biopharmaceutical collaborations to help drive long-term profitable growth for Veracyte.

• Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State

  4/22/2019

  Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis

• Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype

  4/8/2019

  RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries

• Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF

  4/1/2019

  Novel genomic test distinguishes IPF from other lung-scarring diseases without the need for surgery

• Veracyte Announces Participation in the 18th Annual Needham Healthcare Conference

  3/28/2019

  A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

• Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer

  3/25/2019

  Veracyte, Inc. (Nasdaq: VCYT) announced that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes.